Hoping to repeat the success of its mRNA-based COVID-vaccine, Moderna, Inc. has unveiled plans to advance a portfolio of 15 vaccine programs targeting emerging or neglected infectious diseases into clinical studies by 2025.
The biotech will target the "15 priority pathogens" deemed by the World Health Organization (WHO) and the Coalition for Epidemic...